The stock price for Antofagasta found using EPIC: LON:ANTO has stepped up 2.8% or 21.8 points during today’s session so far. Buyers have stayed positive during this period. The periods ...

AstraZeneca plc with EPIC/TICKER (LON:AZN) had its stock rating noted as ‘Unchanged’ with the recommendation being set at ‘SELL’ this morning by analysts at UBS. AstraZeneca plc are listed in ...

AstraZeneca (LON:AZN) today announced that it has completed the previously communicated agreement with Atnahs Pharma to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination). Financial ...

Shares of Anglo American ticker code: LON:AAL has decreased -3.33% or -61.6 points in today’s trading session so far. Sellers were far from a positive bunch during the session. Range ...

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Deutsche Bank. AstraZeneca plc are listed ...

AstraZeneca (LON:AZN) has today announced that it has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist ...

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Kepler Cheuvreux. AstraZeneca plc are listed ...

AstraZeneca plc (LON:AZN) has today announced its full year and Q4 2019 results. AstraZeneca delivered a year of strong revenue growth, supported by the launch of new medicines1 and further good ...

High-level results from the Phase III THALES trial showed AstraZeneca (LON:AZN) Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction ...

High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu, achieved a statistically significant and clinically meaningful improvement in objective response rate ...